Please assess the completion status of the following clinical trial:

Trial Title: A Study of T2000 in Essential Tremor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed essential tremor by NIH criteria~* Significant functional activity limitation due to ET~* Patients who have failed, are inadequately treated or cannot tolerate alternative treatments for ET as well as treatment naïve patients who have considered but declined alternative treatment~Exclusion Criteria:~* Patients adequately controlled without side effects on a current ET treatment~* Pregnant patients or patients who may become pregnant during the study~* Patients with other medical conditions that may cause tremor, such as Parkinson's disease or active hyperthyroidism~* Patients taking medications that might produce tremor or interfere with the evaluation of tremor such as CNS-stimulants or beta-blockers~* Patients who must take medications that alter liver metabolism as well as patients with liver disease or coagulation disorders~* Patients with seizure disorders~* Patients with a history of allergy or hypersensitivity reaction to barbiturates or other related medications, such as phenobarbital or phenytoin~* Patient with significant general medical or clinical laboratory abnormalities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): T2000 dose escalation
- 2 (Type: EXPERIMENTAL): Placebo followed by T2000 dose escalation
- 3 (Type: EXPERIMENTAL): Placebo followed by T2000 dose escalation

Based on this trial design, predict the completion outcome and termination type (if applicable).